INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,459,737 | +127.9% | 402,359 | +36.0% | 0.00% | – |
| Q2 2023 | $3,273,052 | -34.3% | 295,936 | -20.2% | 0.00% | -100.0% |
| Q1 2023 | $4,980,086 | -45.0% | 370,818 | -49.3% | 0.00% | 0.0% |
| Q4 2022 | $9,052,230 | -2.4% | 731,789 | +10.0% | 0.00% | 0.0% |
| Q3 2022 | $9,278,000 | +67.2% | 665,063 | +65.5% | 0.00% | 0.0% |
| Q2 2022 | $5,548,000 | -19.3% | 401,796 | -4.9% | 0.00% | 0.0% |
| Q1 2022 | $6,873,000 | +11.3% | 422,440 | +11.4% | 0.00% | 0.0% |
| Q4 2021 | $6,174,000 | +99.0% | 379,060 | +81.4% | 0.00% | – |
| Q3 2021 | $3,103,000 | -34.5% | 208,944 | -12.0% | 0.00% | – |
| Q2 2021 | $4,741,000 | -13.2% | 237,419 | +0.3% | 0.00% | -100.0% |
| Q1 2021 | $5,461,000 | +7.6% | 236,644 | +15.2% | 0.00% | 0.0% |
| Q4 2020 | $5,076,000 | -36.8% | 205,489 | +6.1% | 0.00% | 0.0% |
| Q3 2020 | $8,033,000 | -25.1% | 193,748 | -13.4% | 0.00% | -50.0% |
| Q2 2020 | $10,723,000 | -15.6% | 223,825 | +10.9% | 0.00% | 0.0% |
| Q1 2020 | $12,702,000 | -47.4% | 201,759 | +3.5% | 0.00% | -33.3% |
| Q4 2019 | $24,147,000 | +205.2% | 194,856 | +63.5% | 0.00% | +200.0% |
| Q3 2019 | $7,911,000 | -23.3% | 119,205 | -8.1% | 0.00% | -50.0% |
| Q2 2019 | $10,320,000 | -63.6% | 129,699 | -48.8% | 0.00% | -50.0% |
| Q1 2019 | $28,343,000 | +191.3% | 253,379 | +162.5% | 0.00% | +100.0% |
| Q4 2018 | $9,730,000 | -14.6% | 96,542 | +7.1% | 0.00% | 0.0% |
| Q3 2018 | $11,393,000 | +7.7% | 90,164 | -28.5% | 0.00% | 0.0% |
| Q2 2018 | $10,581,000 | -33.4% | 126,106 | -51.2% | 0.00% | 0.0% |
| Q1 2018 | $15,891,000 | +167.0% | 258,309 | +153.5% | 0.00% | +100.0% |
| Q4 2017 | $5,952,000 | -71.0% | 101,893 | -71.2% | 0.00% | -66.7% |
| Q3 2017 | $20,530,000 | -46.0% | 353,738 | +12.6% | 0.00% | -57.1% |
| Q2 2017 | $38,047,000 | -18.8% | 314,247 | -24.2% | 0.01% | -22.2% |
| Q1 2017 | $46,865,000 | -3.0% | 414,361 | -6.8% | 0.01% | -18.2% |
| Q4 2016 | $48,302,000 | -38.3% | 444,567 | -6.5% | 0.01% | -38.9% |
| Q3 2016 | $78,268,000 | +8.4% | 475,529 | -6.0% | 0.02% | +5.9% |
| Q2 2016 | $72,180,000 | +28.2% | 505,885 | +15.4% | 0.02% | +21.4% |
| Q1 2016 | $56,319,000 | -6.3% | 438,379 | +8.9% | 0.01% | 0.0% |
| Q4 2015 | $60,116,000 | +13.3% | 402,512 | +25.8% | 0.01% | +7.7% |
| Q3 2015 | $53,049,000 | +115.0% | 319,843 | +212.9% | 0.01% | +62.5% |
| Q2 2015 | $24,676,000 | -2.1% | 102,226 | +14.4% | 0.01% | 0.0% |
| Q1 2015 | $25,198,000 | +111.8% | 89,349 | +17.2% | 0.01% | +100.0% |
| Q4 2014 | $11,896,000 | -40.1% | 76,255 | -9.2% | 0.00% | -33.3% |
| Q3 2014 | $19,875,000 | -3.3% | 83,970 | -3.3% | 0.01% | -14.3% |
| Q2 2014 | $20,544,000 | -4.5% | 86,819 | +33.0% | 0.01% | -12.5% |
| Q1 2014 | $21,523,000 | +813.5% | 65,261 | +89.1% | 0.01% | +700.0% |
| Q4 2013 | $2,356,000 | +217.9% | 34,509 | +221.5% | 0.00% | – |
| Q3 2013 | $741,000 | +29.5% | 10,734 | -15.9% | 0.00% | – |
| Q2 2013 | $572,000 | – | 12,769 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |